Asiatic acid induces endoplasmic reticulum stress and apoptotic death in glioblastoma multiforme cells both in vitro and in vivo
Authors:
- 22 September 2014
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 54 (11) , 1417-1429
Abstract
Glioblastoma multiforme (GBM) is an untreatable malignancy. Existing therapeutic options are insufficient, and adversely affect functional and non‐cancerous cells in the brain impairing different functions of the body. Therefore, there is an urgent need for additional preventive and therapeutic non‐toxic drugs against GBM. Asiatic acid (AsA; 2,3,23‐trihydroxy‐12‐ursen‐28‐oic acid, C30H48O5) is a natural small molecule widely used to treat various neurological disorders, and the present research investigates AsA's efficacy against GBM both in vitro and in vivo. Results showed that AsA treatment (10–100 µM) decreased the human GBM cell (LN18, U87MG, and U118MG) viability, with better efficacy than temozolomide at equimolar doses. Orally administered AsA (30 mg/kg/d) strongly decreased tumor volume in mice when administered immediately after ectopic U87MG xenograft implantation (54% decrease, P ≤ 0.05) or in mice with established xenografts (48% decrease, P ≤ 0.05) without any apparent toxicity. Importantly, AsA feeding (30 mg/kg/twice a day) also decreased the orthotopic U87MG xenografts growth in nude mice as measured by magnetic resonance imaging. Using LC/MS‐MS methods, AsA was detected in mice plasma and brain tissue, confirming that AsA crosses blood‐brain barrier. Mechanistic studies showed that AsA induces apoptotic death by modulating the protein expression of several apoptosis regulators (caspases, Bcl2 family members, and survivin) in GBM cells. Furthermore, AsA induced ER stress (increased GRP78 and Calpain, and decreased Calnexin and IRE1α expression), enhanced free intra‐cellular calcium, and damaged cellular organization in GBM cells. These experimental results demonstrate that AsA is effective against GBM, and advocate further pre‐clinical and clinical evaluations of AsA against GBM.Keywords
Funding Information
- Department of Pharmaceutical Sciences (DOPS)
- NCI RO1 (CA102514)
- CCTSI (5UL1RR025780)
- CCSG (P30CA046934)
This publication has 47 references indexed in Scilit:
- ER–Golgi network—A future target for anti-cancer therapyLeukemia Research, 2009
- Asiatic Acid Induces Colon Cancer Cell Growth Inhibition and Apoptosis through Mitochondrial Death CascadeBiological and Pharmaceutical Bulletin, 2009
- Neuronutrient impact of Ayurvedic Rasayana therapy in brain agingBiogerontology, 2008
- Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calciumCell Death & Differentiation, 2007
- Glioblastoma cell death induced by asiatic acidCell Biology and Toxicology, 2006
- Effect of Silibinin on the Growth and Progression of Primary Lung Tumors in MiceJNCI: Journal of the National Cancer Institute, 2006
- Centella asiatica accelerates nerve regeneration upon oral administration and contains multiple active fractions increasing neurite elongation in-vitroJournal of Pharmacy and Pharmacology, 2005
- Asiatic acid derivatives protect cultured cortical neurons from glutamate-induced excitotoxicity.2002
- Organelle-specific initiation of cell death pathwaysNature Cell Biology, 2001
- Pharmacokinetics of the total triterpenic fraction of Centella asiatica after single and multiple administrations to healthy volunteers. A new assay for asiatic acidJournal of Ethnopharmacology, 1990